Related Experiment Video
Updated: Jul 23, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
David Mutschlechner1, Maximilian Tscharre2,3, Kurt Huber4,5
1Department of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-Gänserndorf, Liechtensteinstraße 67, 2130 Mistelbach, Austria.
Insights
Bempedoic acid significantly reduced major adverse cardiovascular events (MACEs) by lowering non-fatal myocardial infarctions (MI) in hyperlipidaemia patients. However, it did not significantly impact stroke or all-cause mortality rates in this systematic review.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor for cardiovascular mortality and morbidity.
- Bempedoic acid is a novel lipid-lowering agent for patients with hyperlipidaemia who do not achieve LDL-C goals or are statin-intolerant.
- Limited data exist on the safety and cardiovascular outcomes of bempedoic acid.
Conclusions:
- Bempedoic acid effectively reduces non-fatal myocardial infarction in patients with hyperlipidaemia.
- The drug demonstrated no significant impact on stroke incidence or all-cause mortality in the reviewed studies.
- Further research may be warranted to fully elucidate the long-term cardiovascular benefits and safety profile of bempedoic acid.
Aims:
Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular mortality and morbidity. Bempedoic acid represents a promising novel lipid-modifying agent for patients who cannot reach guideline recommended LDL-C goals or statin-intolerant patients, but data on safety and cardiovascular outcomes are limited. We therefore aimed to systematically review randomized controlled trials investigating bempedoic acid vs. placebo in patients with hyperlipidaemia.
Methods:
A systematic search on the databases PubMed, Web of Science, and Embase until 20 March 2023 was performed. All randomized trials comparing bempedoic acid (180 mg daily) with placebo in patients with an indication for lipid-lowering therapy were included. As a primary endpoint, we analysed three-point major adverse cardiovascular events (MACEs) consisting of cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke. The analysis was carried out using the odds ratio (OR) as the outcome measure. Due to the expected heterogeneity across studies, a random-effects model was fitted to the data.
Results:
Out of 258 manuscripts, 10 manuscripts fulfilled the inclusion criteria. In total, these trials included 18 200 patients (9765 on bempedoic acid, 8435 on placebo). Bempedoic acid significantly reduced MACEs compared with placebo (OR 0.84 [95% confidence interval (CI) 0.76-0.96]; P < 0.001; I2 = 0%). The endpoint reduction was driven by a lower rate of non-fatal MI, whereas bempedoic acid had no significant effect on stroke (OR 0.86 [95% CI 0.69-1.08]; P = 0.20, I2 = 0%) and all-cause mortality (OR 1.19 [95% CI 0.73-1.93]; P = 0.49; I2 = 18%).
Conclusion:
Bempedoic acid reduced non-fatal MI in patients with hyperlipidaemia, whereas it had no significant effect on stroke and all-cause mortality.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:27Peripheral Artery Disease III: Interprofessional Care
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...